Roth Capital is sole bookrunning manager; co-manager Monarch assists
By Devika Patel
Knoxville, Tenn., July 21 – iRadimed Corp. said the underwriters for its initial public offering of stock opted to exercise the deal’s $1.89 million greenshoe in full for total proceeds of $14.49 million. The deal was announced June 18 and priced for $12.6 million with the greenshoe on July 16.
The company sold 2,318,400 common shares at $6.25 apiece. Of the shares, 302,400 comprised the fully exercised greenshoe.
Roth Capital Partners was the sole bookrunning manager.
Proceeds will be used for sales and marketing efforts, research and development, working capital and other general corporate purposes.
The provider of non-magnetic intravenous infusion pump systems is based in Winter Springs, Fla. The company intends to list its common stock on the Nasdaq under the symbol “IRMD.”
| Issuer: | iRadimed Corp.
|
| Issue: | Common stock
|
| Amount: | $14.49 million (including $1.89 million greenshoe)
|
| Shares: | 2,318,400
|
| Price: | $6.25
|
| Warrants: | No
|
| Bookrunner: | Roth Capital Partners
|
| Co-manager: | Monarch Capital Group
|
| Announcement date: | June 18
|
| Pricing date: | July 16
|
| Settlement date: | July 21
|
| Stock symbol: | Nasdaq: IRMD
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
